CanSino Biologics Inc. (OTCMKTS:CASBF – Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 485,040 shares, a growth of 4,139.9% from the August 15th total of 11,440 shares. Based on an average daily volume of 279 shares, the days-to-cover ratio is currently 1,738.5 days.
CanSino Biologics Stock Performance
CASBF stock remained flat at C$4.60 during trading on Thursday. The firm has a 50 day moving average of C$3.40 and a 200 day moving average of C$3.56. CanSino Biologics has a 52-week low of C$2.60 and a 52-week high of C$6.99.
About CanSino Biologics
CanSino Biologics Inc is a China-based biopharmaceutical company focused on the research, development and commercialization of vaccine products. Headquartered in Tianjin, the company leverages an adenovirus vector platform to develop single-dose and recombinant vaccines targeting a range of infectious diseases. CanSino’s pipeline includes its authorized COVID-19 vaccine, Convidecia (Ad5-nCoV), as well as candidates for Ebola, influenza and other pathogens.
Since its founding in 2009, CanSino has built end-to-end capabilities spanning antigen discovery, process development and large-scale manufacturing.
Further Reading
- Five stocks we like better than CanSino Biologics
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for CanSino Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CanSino Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
